English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Various viral vectors are being explored for use in vaccines against diseases such as HIV, TB, and malaria. Although unpredicted, the ''STEP'' trial results highlight the importance of safety assessments of candidate vaccines. Safety parameters generally can not be measured directly, but require indirect inference from the frequency of multiple adverse events (AEs). We seek harmonization of AE assessments to maximize their comparability and value across trials of multiple vaccine candidates.

retrovirology

P15-06. Brighton collaboration viral vector vaccines safety working group (V3SWG): maximizing the comparability and value of safety data from HIV vaccine trials